Report Highlights

The United States' Position in the Global Melanoma Supply Chain

The United States is the largest consumer of melanoma therapeutics globally and occupies a dual position in the supply chain: it is a major developer and exporter of branded immuno-oncology biologics, yet a net importer of the active pharmaceutical ingredients and generic chemotherapy components that support treatment. The American Cancer Society projects more than 100,000 new melanoma cases in 2024, sustaining demand for checkpoint inhibitors, targeted BRAF and MEK combinations, and advanced cell therapies. Merck and Bristol Myers Squibb maintain U.S. biologics networks that supply both domestic patients and export channels into Europe and Japan.

Import dependency concentrates in upstream inputs. Ireland and Switzerland supply a large share of finished brand-name oncology biologics, while India and China provide most generic intermediates and injectable chemotherapy APIs. Logistics vulnerability is greatest for autologous cell therapies such as Amtagvi, where patient-specific manufacturing and cryogenic transport concentrate value in a handful of specialized treatment centers.

Growth Drivers Shaping Melanoma Therapy Production in the United States

Adjuvant and combination approvals are expanding treatment volumes. Keytruda's adjuvant indication for resected stage III and IV melanoma, and Opdualag's 2022 approval combining nivolumab and relatlimab for unresectable or metastatic disease, shift demand toward earlier-stage patients and extend infusion-center throughput. Manufacturers respond by adding fill-finish capacity in U.S. plants, reducing dependence on European sterile-fill sites for the highest-volume checkpoint products.

Cell therapy manufacturing is the second driver. Amtagvi, approved by the FDA in February 2024 as the first tumor-infiltrating lymphocyte therapy, requires vein-to-vein logistics that reward regional hubs with apheresis, cell processing, and cryogenic shipping capacity. Diagnostics add a third stream: gene expression profiling tests such as Castle Biosciences' DecisionDx-Melanoma are driving sample logistics for staging decisions across hospital and reference laboratories.

Supply Chain Risks and Trade Barriers

Tariff exposure is the most immediate risk. The Commerce Department's Section 232 investigation into pharmaceutical imports, launched in 2025, threatens duties on branded drugs sourced from abroad, while the EU-U.S. framework caps tariffs on European-origin pharmaceuticals at 15 percent. Companies routing Irish-made or Swiss-made biologics through U.S. fill-finish sites face duty stacking and customs classification disputes that directly affect landed cost.

Raw material and logistics risks compound this exposure. Active pharmaceutical ingredients for generic injectables depend on Indian and Chinese suppliers, and recurring shortages of cisplatin and other sterile injectables have exposed single-source vulnerabilities. Cell therapy cold chains operate within narrow windows from collection to infusion, and a disruption at a regional courier hub can invalidate a patient-specific batch.

Trade and Investment Opportunities in the United States

Subcutaneous reformulation creates an import-substitution play. Opdivo Qvantig, approved by the FDA in December 2024, shifts dosing from lengthy hospital infusion toward faster delivery, requiring new prefilled syringe and auto-injector capacity. U.S. contract manufacturers that can fill these formats domestically capture margin currently earned by European sites.

Inbound investment is most attractive for cell therapy logistics hubs. Operators that build apheresis, cryopreservation, and courier integration near academic centers in the Northeast and Midwest can serve multiple sponsors and lower per-patient cost. Diagnostics laboratories offering prognostic testing with rapid turnaround also have room to expand as payers extend coverage for staging decisions.

Market at a Glance

Leading Market Participants

• Merck & Co.
• Bristol Myers Squibb
• Novartis
• Pfizer
• Roche
• Amgen
• Iovance Biotherapeutics
• Immunocore
• Replimune
• Castle Biosciences

Regulatory and Trade Policy Environment

Oncology biologics enter the U.S. market under FDA Biologics License Applications and follow accelerated approval pathways that have shaped melanoma launches since the 2011 approval of ipilimumab. Pharmaceutical imports are classified under Harmonized Tariff Schedule Chapter 30, and most finished biologics enter at low or zero normal-trade duty rates under longstanding arrangements with Ireland and Switzerland, though Section 232 measures could alter that status.

Pricing policy sets the economics of supply. The Inflation Reduction Act's Medicare drug price negotiation program pressures revenue for mature checkpoint inhibitors, while the BIOSECURE Act restricts federal contracting with certain Chinese contract manufacturers, reshaping sourcing for biologics and peptide intermediates. Manufacturers responding to these rules are expanding U.S. capacity to protect federal reimbursement exposure.

U.S. Melanoma Supply Chain Outlook to 2032

Biosimilar pembrolizumab and nivolumab entries following U.S. patent expiries around 2028 will shift supply from brand-name biologics toward lower-cost manufacturers, with Indian and South Korean biosimilar producers gaining share. Domestic fill-finish capacity built for subcutaneous formats becomes the cost-advantaged asset during this transition.

Cell therapy and bispecific protein production will raise the share of U.S.-manufactured value. Iovance's commercial rollout will require domestic cryogenic logistics, while Immunocore's tebentafusp for uveal melanoma keeps protein-based supply concentrated in specialist sites. Trade flows will tilt toward regional U.S. manufacturing and away from long-haul European air freight across the forecast period.